Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome

NCT02092207 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Syndrome

Interventions

DRUG: KL7016 900mg
DRUG: KL7016 600mg
DRUG: Placebo

Sponsor

Yungjin Pharm. Co., Ltd.